Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on equity (ROE) is N/A as of the fiscal period ended Friday, June 30, 2023.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2023 (2023-06-30): 196.40%.
RETURN ON EQUITY (ROE)
N/A
RETURN ON EQUITY (ROE) AVG TTM
112.27%
RETURN ON EQUITY (ROE) AVG 3Y
288.40%
RETURN ON EQUITY (ROE) AVG 5Y
226.82%
RETURN ON EQUITY (ROE) AVG 10Y
-88.51%
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Omeros Corporation
Market Cap
$1.34B
Return on Equity (ROE)
N/A
TTM Avg
112.27%
3Y Avg
288.40%
5Y Avg
226.82%
Market Cap
$1.33B
Return on Equity (ROE)
N/A
TTM Avg
36.18%
3Y Avg
36.18%
5Y Avg
36.18%
Market Cap
$1.37B
Return on Equity (ROE)
N/A
TTM Avg
-244.46%
3Y Avg
-323.47%
5Y Avg
-258.47%
Market Cap
$1.31B
Return on Equity (ROE)
-210.13%
TTM Avg
-52.98%
3Y Avg
-43.11%
5Y Avg
1.89%
Market Cap
$1.39B
Return on Equity (ROE)
9.00%
TTM Avg
8.29%
3Y Avg
7.90%
5Y Avg
8.39%
Market Cap
$1.40B
Return on Equity (ROE)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.40B
Return on Equity (ROE)
N/A
TTM Avg
41.79%
3Y Avg
41.79%
5Y Avg
41.79%
Market Cap
$1.40B
Return on Equity (ROE)
-38.64%
TTM Avg
-84.50%
3Y Avg
-4452.86%
5Y Avg
-3001.92%
Market Cap
$1.42B
Return on Equity (ROE)
1849.06%
TTM Avg
-120.25%
3Y Avg
-118.83%
5Y Avg
-82.76%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Omeros Corporation (OMER) | $1.34B | N/A | 112.27% | 288.40% | 226.82% |
| Hemab Therapeutics Holdings, Inc. Common Stock (COAG)vs › | $1.33B | N/A | 36.18% | 36.18% | 36.18% |
| Inhibrx Biosciences Inc. (INBX)vs › | $1.37B | N/A | -244.46% | -323.47% | -258.47% |
| Alpha Tau Medical Ltd (DRTS)vs › | $1.31B | -210.13% | -52.98% | -43.11% | 1.89% |
| The Pennant Group, Inc. (PNTG)vs › | $1.39B | 9.00% | 8.29% | 7.90% | 8.39% |
| Braveheart Bio, Inc. (BRVE)vs › | $1.40B | N/A | N/A | N/A | N/A |
| Kailera Therapeutics, Inc. (KLRA)vs › | $1.40B | N/A | 41.79% | 41.79% | 41.79% |
| Taysha Gene Therapies, Inc. (TSHA)vs › | $1.40B | -38.64% | -84.50% | -4452.86% | -3001.92% |
| AnaptysBio, Inc. (ANAB)vs › | $1.42B | 1849.06% | -120.25% | -118.83% | -82.76% |
| Ultragenyx Pharmaceutical Inc. (RARE)vs › | $1.42B | N/A | 247.90% | 18.71% | 1.58% |
ROE
N/A
ROA
43.5%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2023-06-30 | 196.40% |
| 2023-03-31 | 85.06% |
| 2022-12-31 | 55.34% |
| 2021-12-31 | 816.80% |
| 2018-12-31 | -19.50% |
| 2017-09-30 | -614.07% |
| 2015-03-31 | -346.52% |
| 2014-03-31 | -881.60% |
| 2011-09-30 | -627.32% |
| 2011-06-30 | -265.79% |
| 2011-03-31 | -198.56% |
| 2010-12-31 | -142.90% |
| 2010-09-30 | -120.47% |
| 2010-06-30 | -80.42% |
| 2010-03-31 | -60.20% |
| 2009-12-31 | -48.88% |
